Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy
The DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The efficacy of thiazolidinediones, as compared with other oral glucose-lowering medications, in maintaining long-term glycemic control in type 2 diabetes is not known. METHODS: We evaluated rosiglitazone, metformin, and glyburide as initial treatment for recently diagnosed type 2 diabetes in a double-blind, randomized, controlled clinical trial involving 4360 patients. The patients were treated for a median of 4.0 years. The primary outcome was the time to monotherapy failure, which was defined as a confirmed level of fasting plasma glucose of more than 180 mg per deciliter (10.0 mmol per liter), for rosiglitazone, as compared with metformin or glyburide. Prespecified secondary outcomes were levels of fasting plasma glucose and glycated hemoglobin, insulin sensitivity, and beta-cell function. RESULTS: Kaplan-Meier analysis showed a cumulative incidence of monotherapy failure at 5 years of 15% with rosiglitazone, 21% with metformin, and 34% with glyburide. This represents a risk reduction of 32% for rosiglitazone, as compared with metformin, and 63%, as compared with glyburide (P<0.001 for both comparisons). The difference in the durability of the treatment effect was greater between rosiglitazone and glyburide than between rosiglitazone and metformin. Glyburide was associated with a lower risk of cardiovascular events (including congestive heart failure) than was rosiglitazone (P<0.05), and the risk associated with metformin was similar to that with rosiglitazone. Rosiglitazone was associated with more weight gain and edema than either metformin or glyburide but with fewer gastrointestinal events than metformin and with less hypoglycemia than glyburide (P<0.001 for all comparisons). CONCLUSIONS: The potential risks and benefits, the profile of adverse events, and the costs of these three drugs should all be considered to help inform the choice of pharmacotherapy for patients with type 2 diabetes. (ClinicalTrials.gov number, NCT00279045 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“TZDs have a high durability of glycemic response, most likely through a potent effect on preserving b -cell function (196).”
In the citing paper
“However, these bene fi ts must be balanced against possible side effects of fl uid retention and congestive HF (196,197,202), weight gain (196 -198,202,203), and bone fracture (204,205).”
In the citing paper
“In A Diabetes Outcome Progression Trial (ADOPT), rosiglitazone monotherapy was more effective than metformin and glyburide monotherapies in achieving and maintaining fasting plasma glucose below 180 mg/dL (10 mmol/L) among recently diagnosed individuals with type 2 diabetes whose baseline fasting plasma glucose was 126-180 mg/dL (7-10 mmol/L), while glyburide was least effective (107).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [107]
In the citing paper
“In A Diabetes Outcome Progression Trial (ADOPT), rosiglitazone monotherapy was more effective than metformin and glyburide monotherapies in achieving and maintaining fasting plasma glucose below 180 mg/dL (10 mmol/L) among recently diagnosed individuals with type 2 diabetes whose baseline fasting plasma glucose was 126-180 mg/dL (7-10 mmol/L), while glyburide was least effective (107).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [107]
In the citing paper
“The TODAY (Treatment Options for Type 2 Diabetes in Adolescents and Youth) study examined the impact of lifestyle and medications in a young cohort with diabetes duration of less than a year and found glycaemia to be best managed by the combination of rosiglitazone and metformin, with the addition of lifestyle to metformin being no better than metformin alone161.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [161]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023
Self-citationUse and Abuse of HOMA Modeling
Wallace, T. M., Levy, J. C., & Matthews, D. R. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1487 · Cited by 5,114
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Ohkubo, Y., Kishikawa, H., Araki, E., Miyata, T., Isami, S., Motoyoshi, S., Kojima, Y., Furuyoshi, N., & Shichiri, M. (1995) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(95)01064-k · Cited by 3,079
Kahn, S. E. (2003) · Diabetologia · doi:10.1007/s00125-002-1009-0 · Cited by 2,166
Self-citationWeyer, C., Bogardus, C., Mott, D. M., & Pratley, R. E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7231 · Cited by 1,940
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Research works printed but not linked: 3
- 10.1210/jc.82.7.2108 · doi:10.1210/jc.82.7.2108 · Paper page
- Harris SB, 2004, Can Fam Physician, 50, 425
- 10.1210/jc.87.6.2784 · doi:10.1210/jc.87.6.2784 · Paper page
Cited by
Items 301–400 of 1,014
Metformin as an anti-inflammatory agent: a short review
Kristófi, R., & Eriksson, J. W. (2021) · Journal of Endocrinology · doi:10.1530/joe-21-0194 · Cited by 156
Inagaki, N., Kondo, K., Yoshinari, T., Maruyama, N., Susuta, Y., & Kuki, H. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12149 · Cited by 135
Metformin Pharmacogenomics: Current Status and Future Directions
Pawlyk, A. C., Giacomini, K. M., McKeon, C., Shuldiner, A. R., & Florez, J. C. (2014) · Diabetes · doi:10.2337/db13-1367 · Cited by 136
Dennis, J. M., Henley, W. E., Weedon, M. N., Lonergan, M., Rodgers, L. R., Jones, A. G., Hamilton, W. T., Sattar, N., Janmohamed, S., Holman, R. R., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0344 · Cited by 136
Self-citationMetformin – the gold standard in type 2 diabetes: what does the evidence tell us?
Bosi, E. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.01031.x · Cited by 134
Wan, Y. (2010) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2010.08.006 · Cited by 158
Billington, E. O., Grey, A., & Bolland, M. J. (2015) · Diabetologia · doi:10.1007/s00125-015-3660-2 · Cited by 133
Glintborg, D., Andersen, M., Hagen, C., Heickendorff, L., & Hermann, A. P. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2249 · Cited by 133
Reversal of β cell de-differentiation by a small molecule inhibitor of the TGFβ pathway
Blum, B., Roose, A. N., Barrandon, O., Maehr, R., Arvanites, A. C., Davidow, L. S., Davis, J. C., Peterson, Q. P., Rubin, L. L., & Melton, D. A. (2014) · eLife · doi:10.7554/elife.02809 · Cited by 134
Management of diabetic complications: A chemical constituents based approach
Singh, R., Kaur, N., Kishore, L., & Gupta, G. K. (2013) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2013.08.051 · Cited by 146
Thiazolidinediones and Fractures in Men and Women
Dormuth, C. R., Carney, G., Carleton, B., Bassett, K., & Wright, J. M. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.214 · Cited by 134
Sex and gender influences on pharmacological response: an overview
Franconi, F., & Campesi, I. (2014) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2014.922866 · Cited by 132
Hasan, R., Firwana, B., Elraiyah, T. A., Domecq, J. P., Prutsky, G. J., Nabhan, M., Prokop, L. J., Henke, P. K., Τσάπας, Α., Montori, V. M., et al. (2016) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2015.10.005 · Cited by 145
Obesity and Bone Health: A Complex Link
Hou, J., He, C., He, W., Yang, M., Luo, X., & Li, C. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.600181 · Cited by 155
Metformin: Therapeutic profile in the treatment of type 2 diabetes
Bailey, C. J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15663 · Cited by 171
Metabonomic Variations in the Drug-Treated Type 2 Diabetes Mellitus Patients and Healthy Volunteers
Bao, Y., Zhao, T., Wang, X., Qiu, Y., Su, M., Jia, W., & Jia, W. P. (2009) · Journal of Proteome Research · doi:10.1021/pr800643w · Cited by 134
Overview of Newer Agents: Where Treatment Is Going
DeFronzo, R. A. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.12.008 · Cited by 158
Unraveling oxyntomodulin, GLP1's enigmatic brother
Pocai, A. (2012) · Journal of Endocrinology · doi:10.1530/joe-12-0368 · Cited by 130
Cosma, M., Swiglo, B. A., Flynn, D. N., Kurtz, D. M., LaBella, M. L., Mullan, R. J., Elamin, M. B., Erwin, P. J., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2429 · Cited by 129
McIntosh, B., Cameron, C. G., Singh, S. R., Yu, C., Ahuja, T. K., Welton, N. J., & Dahl, M. (2011) · PubMed Central · Cited by 155
RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017
Bajaj, S. (2018) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-018-0604-7 · Cited by 125
Søfteland, E., Meier, J. J., Vangen, B., Toorawa, R., Maldonado-Lutomirsky, M., & Broedl, U. C. (2017) · Diabetes Care · doi:10.2337/dc16-1347 · Cited by 128
Pancreatic β-cell identity in diabetes
Remedi, M. S., & Emfinger, C. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12727 · Cited by 128
Exercise therapy in Type 2 diabetes
Praet, S. F. E., & van Loon, L. J. C. (2009) · Acta Diabetologica · doi:10.1007/s00592-009-0129-0 · Cited by 128
Seino, Y., Terauchi, Y., Osonoi, T., Yabe, D., Abe, N., Nishida, T., Zacho, J., & Kaneko, S. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13082 · Cited by 127
In Vivo Actions of Peroxisome Proliferator–Activated Receptors
Eldor, R., DeFronzo, R. A., & Abdul-Ghani, M. (2013) · Diabetes Care · doi:10.2337/dcs13-2003 · Cited by 126
Metformin Beyond Diabetes: Pleiotropic Benefits of Metformin in Attenuation of Atherosclerosis
Forouzandeh, F., Salazar, G., Patrushev, N., Xiong, S., Hilenski, L., Fei, B., & Alexander, R. W. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.114.001202 · Cited by 126
Update on diabetes mellitus: prevention, treatment, and association with oral diseases
Skamagas, M., Breen, T. L., & LeRoith, D. (2008) · Oral Diseases · doi:10.1111/j.1601-0825.2007.01425.x · Cited by 148
Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta‐analysis
Turner, R. M., Kwok, C. S., Chen‐Turner, C., Maduakor, C. A., Singh, S., & Loke, Y. K. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12306 · Cited by 127
Williams-Herman, D., Johnson, J., Teng, R., Luo, E., Davies, M. J., Kaufman, K. D., Goldstein, B. J., & Amatruda, J. M. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990802705679 · Cited by 127
Novel insights into the relationship between diabetes and osteoporosis
de Paula, F. J. A., Horowitz, M. C., & Rosen, C. J. (2010) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1135 · Cited by 126
Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug
Nesti, L., Tricò, D., Mengozzi, A., & Natali, A. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01294-7 · Cited by 124
Singh, S., Singh, P. P., Singh, A. G., Murad, H. M., McWilliams, R. R., & Chari, S. T. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.7 · Cited by 123
Deacon, C. F., & Holst, J. J. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.824966 · Cited by 122
Pioglitazone and Risk for Bone Fracture: Safety Data from a Randomized Clinical Trial
Viscoli, C. M., Inzucchi, S. E., Young, L. H., Insogna, K. L., Conwit, R., Furie, K. L., Gorman, M., Kelly, M. A., Lovejoy, A. M., Kernan, W. N., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3237 · Cited by 124
“A Diabetes Outcome Progression Trial (ADOPT) involving patients with type 2 diabetes (7).”
BackgroundMethodInfluentialPantalone, K. M., Kattan, M. W., Yu, C., Wells, B. J., Arrigain, S., Jain, A., Atreja, A., & Zimmerman, R. S. (2009) · Acta Diabetologica · doi:10.1007/s00592-008-0090-3 · Cited by 123
Defects in Insulin Secretion and Action in the Pathogenesis of Type 2 Diabetes Mellitus
Tripathy, D., & Chávez, A. O. (2010) · Current Diabetes Reports · doi:10.1007/s11892-010-0115-5 · Cited by 146
Tokubuchi, I., Tajiri, Y., Iwata, S., Hara, K., Wada, N., Hashinaga, T., Nakayama, H., Mifune, H., & Yamada, K. (2017) · PLOS ONE · doi:10.1371/journal.pone.0171293 · Cited by 121
New Drugs for Type 2 Diabetes Mellitus: What is their Place in Therapy?
Krentz, A. J., Patel, M., & Bailey, C. J. (2008) · Drugs · doi:10.2165/00003495-200868150-00005 · Cited by 141
SERENADE: The Study Evaluating Rimonabant Efficacy in Drug-Naive Diabetic Patients
Rosenstock, J., Hollander, P., Chevalier, S., Iranmanesh, A., & for the SERENADE Study Group (2008) · Diabetes Care · doi:10.2337/dc08-0386 · Cited by 123
Osteoporosis-associated Fracture and Diabetes
Kurra, S., Fink, D. A., & Siris, E. S. (2013) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.09.004 · Cited by 133
Clinical Considerations for Use of Initial Combination Therapy in Type 2 Diabetes
Cahn, A., & Cefalu, W. T. (2016) · Diabetes Care · doi:10.2337/dcs15-3007 · Cited by 118
Dennis, J. M. (2020) · Diabetes · doi:10.2337/dbi20-0002 · Cited by 119
The Record on Rosiglitazone and the Risk of Myocardial Infarction
Psaty, B. M., & Furberg, C. D. (2007) · New England Journal of Medicine · doi:10.1056/nejme078116 · Cited by 121
Beyond BMI: the need for new guidelines governing the use of bariatric and metabolic surgery
Cummings, D. E., & Cohen, R. V. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70198-0 · Cited by 116
Ligands for the Nuclear Peroxisome Proliferator-Activated Receptor Gamma
Sauer, S. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.06.010 · Cited by 133
Meneilly, G. S., Knip, A., Miller, D. B., Sherifali, D., Tessier, D., & Zahedi, A. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.021 · Cited by 144
The RISE Consortium, Ehrmann, D. A., Temple, K. A., Rue, A., Barengolts, E., Mokhlesi, B., Van Cauter, E., Sam, S., Miller, M. A., Kahn, S. E., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0243 · Cited by 115
Self-citationMcGuire, D. K., & Inzucchi, S. E. (2008) · Circulation · doi:10.1161/circulationaha.107.704080 · Cited by 122
Type 2 diabetes mellitus: epidemiology, pathophysiology, unmet needs and therapeutical perspectives
Virally, M., Blickle, J., Girard, J. R., Halimi, S., Simon, D., & Guillausseau, P.-J. (2007) · Diabetes & Metabolism · doi:10.1016/j.diabet.2007.07.001 · Cited by 160
The Treatment of Type 2 Diabetes
Pfeiffer, A. F. H., & Klein, H. H. (2014) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2014.0069 · Cited by 202
Montanya, E., & Sesti, G. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.11.034 · Cited by 126
Heutling, D., Schulz, H., Nickel, I., Kleinstein, J., Kaltwasser, P., Westphal, S., Mittermayer, F., Wolzt, M., Krzyzanowska, K., Randeva, H., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0842 · Cited by 117
Genetics Insights in the Relationship Between Type 2 Diabetes and Coronary Heart Disease
Goodarzi, M. O., & Rotter, J. I. (2020) · Circulation Research · doi:10.1161/circresaha.119.316065 · Cited by 141
Do sulphonylureas still have a place in clinical practice?
Khunti, K., Chatterjee, S., Gerstein, H. C., Zoungas, S., & Davies, M. J. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30025-1 · Cited by 116
Diabesity: therapeutic options
Colagiuri, S. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01182.x · Cited by 118
PPAR‐γ Agonists and Their Effects on IGF‐I Receptor Signaling: Implications for Cancer
Belfiore, A., Genua, M., & Malaguarnera, R. (2009) · PPAR Research · doi:10.1155/2009/830501 · Cited by 115
Maloney, A., Rosenstock, J., & Fonseca, V. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1307 · Cited by 115
Thiazolidinediones and cancer: results of a meta-analysis of randomized clinical trials
Monami, M., Dicembrini, I., & Mannucci, E. (2013) · Acta Diabetologica · doi:10.1007/s00592-013-0504-8 · Cited by 119
Brown, M. L., Yukata, K., Farnsworth, C. W., Chen, D.-G., Awad, H., Hilton, M. J., O'Keefe, R. J., Xing, L., Mooney, R. A., & Zuscik, M. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099656 · Cited by 114
Aquilante, C. L. (2010) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.09.154 · Cited by 137
Nauck, M. A., Del Prato, S., Durán‐García, S., Rohwedder, K., Langkilde, A. M., Sugg, J., & Parikh, S. J. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12327 · Cited by 113
Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future
Davidson, M. A., Mattison, D. R., Azoulay, L., & Krewski, D. (2018) · Critical Reviews in Toxicology · doi:10.1080/10408444.2017.1351420 · Cited by 112
Fracture Risk Assessment in Patients With Diabetes Mellitus
Poiană, C., & Capatina, C. A.-M. (2017) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2017.06.011 · Cited by 127
Beta-Cell Mass in Obesity and Type 2 Diabetes, and Its Relation to Pancreas Fat: A Mini-Review
Inaishi, J., & Saisho, Y. (2020) · Nutrients · doi:10.3390/nu12123846 · Cited by 107
Osteoporosis and risk of fracture in patients with diabetes: an update
Montagnani, A., Gonnelli, S., Alessandri, M., & Nuti, R. (2011) · Aging Clinical and Experimental Research · doi:10.1007/bf03351073 · Cited by 123
DPP-4 inhibitors in the treatment of type 2 diabetes
Duez, H., Cariou, B., & Staels, B. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.11.028 · Cited by 110
Kalra, S., Aamir, A., Raza, A., Das, A., Azad Khan, A., Shrestha, D., Qureshi, M. F., Fariduddin, M., Pathan, M. F., Jawad, F., et al. (2015) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.163171 · Cited by 111
The Risk of Fractures Associated with Thiazolidinediones: A Self-controlled Case-Series Study
Douglas, I. J., Evans, S. J., Pocock, S., & Smeeth, L. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000154 · Cited by 112
Bunck, M. C., Eliasson, B., Cornér, A., Heine, R. J., Shaginian, R. M., Taskinen, M. ‐., Yki‐Järvinen, H., Smith, U., & Diamant, M. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01355.x · Cited by 110
GLP-1 based therapeutics: simultaneously combating T2DM and obesity
Heppner, K. M., & Perez-Tilve, D. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00092 · Cited by 115
3ª Diretriz Brasileira de Transplante Cardíaco
Bacal, F., Marcondes‐Braga, F. G., Rohde, L. E. P., Xavier, J. L., Brito, F. D. S., Moura, L. Z., Colafranceschi, A. S., Lavagnoli, C. F. R., Gelape, C. L., Almeida, D. R., et al. (2018) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20180153 · Cited by 178
The management of gestational diabetes
Cheung, W. (2009) · Vascular Health and Risk Management · doi:10.2147/vhrm.s3405 · Cited by 110
Kim, H.-S., Hwang, Y.-C., Koo, S.-H., Park, K. S., Lee, M.-S., Kim, K.-W., & Lee, M.-K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0050128 · Cited by 110
Zhao, H.-L., Sui, Y., Qiao, C., Yip, K. Y.-L., Leung, R. K. K., Tsui, S. K., Lee, H.-M., Wong, H. K. T., Zhu, X., Siu, J. J., et al. (2012) · Diabetes · doi:10.2337/db11-1164 · Cited by 114
Variants in Pharmacokinetic Transporters and Glycemic Response to Metformin: A Metgen Meta‐Analysis
Dujic, T., Zhou, K., Yee, S., van Leeuwen, N., de Keyser, C., Javorský, M., Goswami, S., Zaharenko, L., Hougaard Christensen, M., Out, M., et al. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.567 · Cited by 108
Nabrdalik, K., Skonieczna‐Żydecka, K., Irlik, K., Hendel, M., Kwiendacz, H., Łoniewski, I., Januszkiewicz, K., Gumprecht, J., & Lip, G. Y. H. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.975912 · Cited by 125
Benvenuti, S., Cellai, I., Luciani, P., Deledda, C., Baglioni, S., Giuliani, C., Saccardi, R., Mazzanti, B., Pozzo, S. D., Mannucci, E., et al. (2007) · Journal of Endocrinological Investigation · doi:10.1007/bf03350807 · Cited by 122
Nieuwenhuis-Ruifrok, A. E., Kuchenbecker, W. K. H., Hoek, A., Middleton, P., & Norman, R. J. (2008) · Human Reproduction Update · doi:10.1093/humupd/dmn043 · Cited by 110
Oral anti-diabetic drugs and fracture risk, cut to the bone: safe or dangerous? A narrative review
Palermo, A., D’Onofrio, L., Eastell, R., Schwartz, A. V., Pozzilli, P., & Napoli, N. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3123-0 · Cited by 114
He, H., Yang, D., Ma, L., Luo, Z., Ma, S., Feng, X., Cao, T., Yan, Z., Liu, D., Tepel, M., et al. (2010) · Hypertension · doi:10.1161/hypertensionaha.109.143958 · Cited by 121
Thiazolidinediones as anti‐inflammatory and anti‐atherogenic agents
Ceriello, A. (2008) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.790 · Cited by 109
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R. S., & Zinman, B. (2007) · Diabetologia · doi:10.1007/s00125-007-0873-z · Cited by 122
Self-citationHepatic Notch Signaling Correlates With Insulin Resistance and Nonalcoholic Fatty Liver Disease
Valenti, L., Mendoza, R. M., Rametta, R., Maggioni, M., Kitajewski, C., Shawber, C. J., & Pajvani, U. B. (2013) · Diabetes · doi:10.2337/db13-0769 · Cited by 111
Shared Decision-Making in Diabetes Care
Tamhane, S. U., Rodríguez‐Gutiérrez, R., Hargraves, I. G., & Montori, V. M. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0688-0 · Cited by 123
Targeting β-Cell Function Early in the Course of Therapy for Type 2 Diabetes Mellitus
Leahy, J. L., Hirsch, I. B., Peterson, K. A., & Schneider, D. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0668 · Cited by 108
Coronary heart disease outcomes in patients receiving antidiabetic agents
McAfee, A. T., Koro, C., Landon, J., Ziyadeh, N., & Walker, A. M. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1443 · Cited by 109
Hensen, J., Howard, C. P., Walter, V., & Thuren, T. Y. (2013) · Diabetes & Metabolism · doi:10.1016/j.diabet.2013.07.003 · Cited by 115
Diabetes and fractures: an overshadowed association
Khazai, N. B., Beck, G. R., & Umpierrez, G. E. (2009) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e328331c7eb · Cited by 106
Regulation of glucose homoeostasis by brown adipose tissue
Peirce, V. J., & Vidal‐Puig, A. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70055-x · Cited by 121
Giaccari, A., Sorice, G. P., & Muscogiuri, G. (2009) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2009.03.018 · Cited by 121
How Doctors Choose Medications to Treat Type 2 Diabetes
Grant, R. W., Wexler, D. J., Watson, A. J., Lester, W. T., Cagliero, E., Campbell, E. G., & Nathan, D. M. (2007) · Diabetes Care · doi:10.2337/dc06-2499 · Cited by 106
2024 EACTS Guidelines on perioperative medication in adult cardiac surgery
Jeppsson, A., (Sweden), (.-C., Rocca, B., (Italy), (.-C., Hansson, E. C., (Sweden), Guðbjartsson, T., (Iceland), James, S. K., (Sweden), et al. (2024) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezae355 · Cited by 129
Targeting β-Cell Mass in Type 2 Diabetes: Promise and Limitations of New Drugs Based on Incretins
Salehi, M., Aulinger, B. A., & D'Alessio, D. A. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0031 · Cited by 109
Berberoglu, Z., Gursoy, A., Bayraktar, N., Yazici, A. C., Bascil Tutuncu, N., & Guvener Demirag, N. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0431 · Cited by 108
Kowaltowski, A. J., & Abdulkader, F. (2020) · Springer eBooks · doi:10.1007/978-3-030-50968-2_9 · Cited by 106
Shuster, J. J., Jones, L. S., & Salmon, D. A. (2007) · Statistics in Medicine · doi:10.1002/sim.3060 · Cited by 105
We Can Change the Natural History of Type 2 Diabetes
Phillips, L. S., Ratner, R. E., Buse, J. B., & Kahn, S. E. (2014) · Diabetes Care · doi:10.2337/dc14-0817 · Cited by 103
Self-citationOsteoporosis after stroke: a review of the causes and potential treatments
Carda, S., Cisari, C., Invernizzi, M., & Bevilacqua, M. (2009) · Cerebrovascular Diseases · doi:10.1159/000226578 · Cited by 104
“Thiazolidine diones, a class of oral antidiabetic drugs approved for type II diabetes mellitus, can have a negative effect on bone mass. Rosiglitazone and pioglitazone seem to increase the risk of fractures in women [”
BackgroundRetractedDeFronzo, R. A., Triplitt, C., Qu, Y., Lewis, M. S., Maggs, D., & Glass, L. C. (2010) · Diabetes Care · doi:10.2337/dc09-1521 · Cited by 104
Metadata
- Authors
- Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., & Viberti, G.
- Affiliations
- University of Washington (US)
- The University of Texas at San Antonio Health Science Center (US)
- GlaxoSmithKline (United States) (US)
- University of Michigan (US)
- Oxford Centre for Diabetes, Endocrinology and Metabolism (GB)
- George Washington University (US)
- Mount Sinai Hospital (CA)
- University of London (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-12-07
- Volume
- 355
- Issue
- 23
- Pages
- 2427-2443
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2081276121
- Cited by
- 2,962
- References
- 37
- Citations by year
- 2026: 48 · 2025: 64 · 2024: 77 · 2023: 66 · 2022: 88 · 2021: 98 · 2020: 120 · 2019: 102 · 2018: 120 · 2017: 139 · 2016: 163 · 2015: 158 · 2014: 181 · 2013: 202 · 2012: 180
- FWCI
- 163.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, rosiglitazone, metformin, glibenclamide, thiazolidinediones, glycemic control, fasting blood glucose, HbA1c, insulin sensitivity, beta-cell function, cardiovascular events, congestive heart failure, hypoglycemia, weight gain, edema, gastrointestinal adverse effects, drug selection
- MeSH terms
- Rosiglitazone, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glyburide, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Cholesterol, LDL, Male, Metformin, Middle Aged, Weight Gain, Proportional Hazards Models, Treatment Outcome, Thiazolidinediones, Waist-Hip Ratio, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.